H O Nazlioglu1, I Ercan, T Bilgin, S Ozuysal. 1. Department of Pathology, Uludag University School of Medicine, Bursa, Turkey. hulyaozturk@uludag.edu.tr
Abstract
PURPOSE: We aimed to examine p16 protein expression in ovarian serous neoplasms along with normal ovarian tissues. MATERIALS AND METHODS: P16 expression was immunhistochemically evaluated in 86 ovarian serous neoplasms (21 cystadenomas, 20 borderline tumors and 45 carcinomas) and 21 non-neoplastic ovarian tissue. The results were also compared with histopathological grade in serous adenocarcinomas. RESULTS: P16 expression rates for benign, borderline ovarian tumors and ovarian cancer were 14.2%, 85% and 86.6%, respectively. It was significantly higher in carcinomas (p < 0.001) and borderline tumors (p < 0.001) compared to cystadenomas. No immunoreactivity was found in the non-neoplastic ovarian surface epithelial cells. The percentage of p16 expression did not change significantly with histological grade in carcinomas. CONCLUSION: P16 expression is strong and widespread involving most tumor cells in serous papillary ovarian carcinomas, and is probably an early event.
PURPOSE: We aimed to examine p16 protein expression in ovarian serous neoplasms along with normal ovarian tissues. MATERIALS AND METHODS:P16 expression was immunhistochemically evaluated in 86 ovarian serous neoplasms (21 cystadenomas, 20 borderline tumors and 45 carcinomas) and 21 non-neoplastic ovarian tissue. The results were also compared with histopathological grade in serous adenocarcinomas. RESULTS:P16 expression rates for benign, borderline ovarian tumors and ovarian cancer were 14.2%, 85% and 86.6%, respectively. It was significantly higher in carcinomas (p < 0.001) and borderline tumors (p < 0.001) compared to cystadenomas. No immunoreactivity was found in the non-neoplastic ovarian surface epithelial cells. The percentage of p16 expression did not change significantly with histological grade in carcinomas. CONCLUSION:P16 expression is strong and widespread involving most tumor cells in serous papillary ovarian carcinomas, and is probably an early event.
Authors: Emiliano Cocco; Yang Deng; Erik M Shapiro; Ileana Bortolomai; Salvatore Lopez; Ken Lin; Stefania Bellone; Jiajia Cui; Gulden Menderes; Jonathan D Black; Carlton L Schwab; Elena Bonazzoli; Fan Yang; Federica Predolini; Luca Zammataro; Gary Altwerger; Christopher de Haydu; Mitchell Clark; Julio Alvarenga; Elena Ratner; Masoud Azodi; Dan-Arin Silasi; Peter E Schwartz; Babak Litkouhi; W Mark Saltzman; Alessandro D Santin Journal: Mol Cancer Ther Date: 2016-12-12 Impact factor: 6.261